Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
about
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Pazopanib versus sunitinib for ...... ients with poor-risk features.
@en
Pazopanib versus sunitinib for ...... ients with poor-risk features.
@nl
type
label
Pazopanib versus sunitinib for ...... ients with poor-risk features.
@en
Pazopanib versus sunitinib for ...... ients with poor-risk features.
@nl
prefLabel
Pazopanib versus sunitinib for ...... ients with poor-risk features.
@en
Pazopanib versus sunitinib for ...... ients with poor-risk features.
@nl
P2093
P2860
P1476
Pazopanib versus sunitinib for ...... ients with poor-risk features.
@en
P2093
Inkeun Park
Jae Lyun Lee
Jwa Hoon Kim
P2860
P2888
P304
P356
10.1007/S00280-016-3093-8
P577
2016-06-21T00:00:00Z
P6179
1046959637